There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (NASDAQ: BMRN) and Wright Medical Group (NASDAQ: WMGI) with bullish sentiments.
BioMarin (NASDAQ: BMRN)
Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin (NASDAQ: BMRN) today and set a price target of $112. The company’s shares closed on Friday at $88.88.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.3% and a 45.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $117.46, representing a 32.2% upside.
In a report issued on May 15, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $101 price target.
See today’s analyst top recommended stocks >>
Wright Medical Group (NASDAQ: WMGI)
In a report released today, Craig Bijou from Cantor Fitzgerald reiterated a Buy rating on Wright Medical Group (NASDAQ: WMGI), with a price target of $30. The company’s shares closed on Friday at $24.80.
Bijou commented:
“We reiterate our Overweight rating and a 12-month price target of $30 on shares of WMGI. We think WMGI is positioned to outperform expectations in 2018 with multiple drivers across each of its three primary segments (lower extremities, upper extremities, and biologics) to accelerate growth. We see WMGI’s valuation as attractive as we expect innovative products to help WMGI to capitalize on the evolving market trends. Valuation Summary We base our $30 price target on a 4.5x EV/Sales multiple on our 2019.”
According to TipRanks.com, Bijou is a 4-star analyst with an average return of 27.5% and a 70.8% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Stryker Corporation.
Wright Medical Group has an analyst consensus of Strong Buy, with a price target consensus of $27.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
